Oral VK2735
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Viking Therapeutics · Phase 2 · Completed · Enrollment 280
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo Assignment | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #1) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #2) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #3) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #4) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #5) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Active Assignment (Dose #6) | Obesity or overweight | n/r | n/r | n/r | n/r |